Alexander Kristian
Overview
Explore the profile of Alexander Kristian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Egeland E, Seip K, Skourti E, Oy G, Pettersen S, Pandya A, et al.
Br J Cancer
. 2024 Oct;
131(10):1656-1667.
PMID: 39390250
Background: Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with...
2.
Bohnke N, Indrevoll B, Hammer S, Papple A, Kristian A, Briem H, et al.
Eur J Nucl Med Mol Imaging
. 2023 Oct;
51(3):669-680.
PMID: 37882848
Purpose: PSMA (prostate-specific membrane antigen) is highly expressed on prostate cancer (PrCa) cells and extensively used as a homing target for PrCa treatment. Most prominently, PSMA-targeting conjugate PSMA-617, carrying a...
3.
Karlsson J, Hagemann U, Cruciani V, Schatz C, Grant D, Ellingsen C, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444529
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-30% of breast cancers but has low expression in normal tissue, making it attractive for targeted alpha therapy (TAT). HER2-positive...
4.
Zitzmann-Kolbe S, Kristian A, Zopf D, Kamfenkel C, Politz O, Ellingsen C, et al.
Mol Cancer Ther
. 2023 Jun;
22(9):1073-1086.
PMID: 37365121
Targeted alpha therapies (TAT) are an innovative class of therapies for cancer treatment. The unique mode-of-action of TATs is the induction of deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as...
5.
Berg-Larsen A, Mobergslien A, Moen I, Petros G, Kristian A, Gunvaldsen K, et al.
Front Med (Lausanne)
. 2022 Dec;
9:1033303.
PMID: 36457578
Targeted thorium-227 conjugates comprise the combination of a monoclonal antibody with specificity for a tumor cell antigen and a 3,2-HOPO chelator enabling complexation of thorium-227 (Th-227). The radiolabeled conjugate functions...
6.
Broer L, Knapen D, Suurs F, Moen I, Giesen D, Waaijer S, et al.
J Nucl Med
. 2022 Apr;
63(11):1715-1721.
PMID: 35422447
The mesothelin (MSLN)-targeted Th conjugate is a novel α-therapy developed to treat MSLN-overexpressing cancers. We radiolabeled the same antibody-chelator conjugate with Zr to evaluate whether PET imaging with Zr-MSLN matches...
7.
Hammer S, Hagemann U, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S, et al.
Clin Cancer Res
. 2019 Dec;
26(8):1985-1996.
PMID: 31831560
Purpose: Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC). PSMA-targeted alpha therapy (TAT) has shown early signs of activity in patients...
8.
Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann U, et al.
Pharmaceuticals (Basel)
. 2019 Oct;
12(4).
PMID: 31618864
Targeted thorium-227 conjugates (TTCs) represent a novel class of therapeutic radiopharmaceuticals for the treatment of cancer. TTCs consist of the alpha particle emitter thorium-227 complexed to a 3,2-hydroxypyridinone chelator conjugated...
9.
Pitman K, Alluri S, Kristian A, Aarnes E, Lyng H, Riss P, et al.
Eur J Nucl Med Mol Imaging
. 2019 Jul;
46(10):2190-2198.
PMID: 31264167
Purpose: F-fluoroaminosuberic acid (F-FASu) is a recently developed amino acid tracer for positron emission tomography (PET) of oxidative stress that may offer improved tumour assessment over the conventional tracer F-fluorodeoxyglucose...
10.
Wickstroem K, Hagemann U, Kristian A, Ellingsen C, Sommer A, Ellinger-Ziegelbauer H, et al.
Int J Radiat Oncol Biol Phys
. 2019 Jul;
105(2):410-422.
PMID: 31255687
Purpose: Fibroblast growth factor receptor 2 (FGFR2) has been previously reported to be overexpressed in several types of cancer, whereas the expression in normal tissue is considered to be moderate...